Sweden's Orexo Q3 revenue falls sharply, net loss widens

By Reuters News


Overview

  • Sweden specialty pharma firm's Q3 revenue fell sharply yr/yr to SEK 0.8 mln

  • Company posted wider Q3 net loss and negative EPS

  • Board announced SEK 250 mln rights issue after quarter-end to bolster finances


Outlook

  • Company did not provide specific financial guidance for the current or coming periods in the press release


Result Drivers

  • LOW REVENUE - Co attributed weak Q3 revenue to ongoing transformation and absence of major product launches or commercial activities

  • R&D INVESTMENT - Operating expenses remained high, with 48% spent on research and development

  • PIPELINE PROGRESS - Co highlighted regulatory milestones for Izipry, OX640 and OX390 as key operational achievements in the quarter


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

SEK 800,000

SEK 4.75 mln (2 Analysts)

Q3 Loss Per Share

SEK 3.36

Q3 EBIT

-SEK 98.50 mln

Q3 EBITDA

-SEK 90.40 mln


Analyst Coverage

  • The one available analyst rating on the shares is "buy"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Orexo AB is SEK38.25, about 615% above its October 21 closing price of SEK5.35


Reuters Recommended Reads

  • Oct 21 - Medical gear maker Getinge beats Q3 profit estimates on pricing, product mix

  • Oct 19 - Germany's Merck buys Silence Therapeutics in $1.3 billion RNA drug deal

  • Oct 19 - France's Poxel Q3 revenue rises on higher TWYMEEG royalties


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.